effect of interleukin 36Gene therapy in the regression of tumor

Cancer immunotherapy attempts to stimulate the immune system to reject and destroy tumors and is one of the cancer treatment strategies. Recently, interluekin36 [IL36] has been used as immunotherapeutic agents in cancer gene therapy. Present study investigated that the IL36 gene therapy effects on the regression of tumor masses in mouse model. Aim of this study is determination of the gene therapy effects by IL36 in the regression of tumor masses in mouse model. To study the therapeutic efficacy of this cytokine, WEHI-164 tumor cells were transected with mIL36 plasmids. ELISA test was used to check cytokine production by transected cells. To establish fibro sarcoma mouse model, Tumoral transfected cells were injected subcutaneously to inoculate tumor in BALB/C mice. Tumor volumes were measured by caliper. Mice were sacrificed and tumors were extracted. The expression of IL36 and IFN-gamma was studied with Real-time PCR and immunoblotting. The expression of Ki-67 [a tumor proliferation marker] in tumor masses was studied by immunohistochemistry staining. In this study we had 2 groups which are treated with IL-36 and Untreated with IL-36 as a blank. The group treated with IL36 indicated decrease of tumor mass volume [p<0.001]. The results of western blotting and real-time PCR showed the IL36 expression increased in the group treated with IL36 [with relative expression of 1.9]. Immunohistochemistry staining indicated that the Ki-67expression has been reduced in the group interfered with IL36. IL36 gene therapy has therapeutic effects on the regression of tumor masses in fibro sarcoma mouse model

Elevated levels of interleukin-23 in sera of patients with pemphigus vulgaris

Pemphigus vulgaris, a chronic mucocutaneous disease, is the most prevalent type of pemphigus which manifests with development of bullae and erosions on skin and mucosal membranes. To investigate the potential role of IL-23 in pemphigus vulgaris. In this study, 30 patients with pemphigus vulgaris and 30 healthy individuals were selected according to inclusion and exclusion criteria. Measurement of IL-23 serum levels in blood samples was conducted by ELISA. Data was analyzed using Student's t-test for comparison of IL-23 levels between the two groups. Mean serum levels of IL-23 in patients with pemphigus and healthy controls were 25.1 +/- 4.2 and 17.9 +/- 4.7 pg/ml, respectively [p<0.05]. Based on the findings of this study, serum levels of IL-23 were higher in patients with pemphigus in comparison to healthy individuals with no clinical significance